Recent News Relating to Our June Newsletter

1. Treatment Action Group statement on bedaquiline unaffordability

Pharmaceutical negotiations continue to stand in the way as the Treatment Action Group strives for a lower bedaquiline price grounded in evidence.

2. Johnson & Johnson TB drug price reduction is important step, and governments need to urgently scale up better treatment

J&J faces pressure to reduce their bedaquiline price to $1/day so governments can replace their painful and risky DR-TB treatments with this oral tablet.

Recent News (From our June 2020 Newsletter)

1. FDA Approves Pediatric Formulation of Bedaquiline for Multidrug-Resistant TB
Bedaquiline first received approval from the FDA in 2012 for use in adult patients. Now, the FDA has given Johnson & Johnson accelerated approval to use the drug on pediatric patients five years and older. You can access the FDA’s updated label for the drug here.

2. Tuberculosis in Children: Underdiagnosed and Undertreated
A deeper dive into comprehensive, up-to-date information on treating tuberculosis in children.

3. TB Alliance Commercialization Partner, Mylan, Launches Named Patient Access Program for Pretomanid as part of New Regimen
Mylan’s new Named Patient Access Program has been designed to make pretomanid accessible in countries previously lacking access to the drug.

Recent news (from our May 2020 Newsletter)

1. IMPORTANT NEWS: INCREASED ACCESS TO PRETOMANID/BPaL
Hope of a cure for individuals with XDR-TB.

2. WHO launches online course to improve diagnosis of drug-resistant TB

WHO/Europe has launched a new online course to strengthen the capacity to diagnose drug-resistant tuberculosis (DR-TB) using molecular techniques. This free course, entitled “Drug-resistant tuberculosis: how to interpret rapid molecular test results”, is available on the OpenWHO platform and includes opportunities for participants throughout the world to seek expert advice for their diagnostic questions.

3. Korea upgrades guidelines for multidrug-resistant TB
Korean patients with multidrug-resistant tuberculosis (TB) will likely get faster and better treatment than now.

Previous news

EMA panel backs pretomanid for drug-resistant TB

Posted on 23 Apr 2020

The Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA) has recommended approval of pretomanid FGK (FGK Representative Service GmbH) for drug-resistant tuberculosis (TB).

Webinar: Hear the latest about the NiX-TB regimen for XDR-TB; Slides and Recording here!

Posted on 30 Mar 2020

On March 26, 2020, RESIST-TB hosted a webinar featuring Dr. Dan Everitt to discuss the recently published work on the NiX-TB trial, which focuses on treatment of extensively drug-resistant tuberculosis (XDR-TB). To read the publication, the article can be found below (publication #2). The presentation slides and recording have been posted here.

WHO announces updates on new molecular assays for the diagnosis of TB and drug resistance

Posted on 16 Jan 2020
Significant improvements to the diagnosis of tuberculosis (TB) and rifampicin resistance in adults and children are expected, following key updates on new molecular assays, announced by the World Health Organization (WHO

Webinar: Advocacy for access to DR-TB treatment – webinar materials now available online

Posted on 16 Jan 2020
The TB Europe Coalition conducted a webinar on 13 November 2019 on advocating for the new guidelines on drug-resistant TB (DR-TB) treatment.